38396-39-3
38396-39-3
Chemical Structure
Bupivacaine
- CAS No.: 38396-39-3
- Formula:C18H28N2O
- Molecular Weight:288.43
IUPAC Name: 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
InChIKey: LEBVLXFERQHONN-UHFFFAOYSA-N
SMILES: O=C(C1N(CCCC)CCCC1)NC2=C(C)C=CC=C2C
Biological Activity: Bupivacaine is a NMDA receptor inhibitor. Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine can be used for the research of chronic pain[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bupivacaine | 99.95% | Bupivacaine is a NMDA receptor inhibitor. Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine can be used for the research of chronic pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bupivacaine (Standard) | ≥98% | Bupivacaine (Standard) is the analytical standard of Bupivacaine. This product is intended for research and analytical applications. Bupivacaine is a NMDA receptor inhibitor. Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine can be used for the research of chronic pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bupivacaine-d9 | 99.04% | Bupivacaine-d99 is a deuterium labeled Bupivacaine. Bupivacaine is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine can be used for the research of chronic pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Meaghan A Paganelli, et al. Actions of Bupivacaine, a widely used local anesthetic, on NMDA receptor responses. J Neurosci. 2015 Jan 14;35(2):831-42. [Content Brief]
- [2]. Alexander P Schwoerer, et al. A Comparative Analysis of Bupivacaine and Ropivacaine Effects on Human Cardiac SCN5A Channels. Anesth Analg. 2015 Jun;120(6):1226-34. [Content Brief]
- [3]. Carsten Stoetzer, et al. Inhibition of Voltage-Gated Na+ Channels by Bupivacaine Is Enhanced by the Adjuvants Buprenorphine, Ketamine, and Clonidine. Reg Anesth Pain Med.Jul/Aug 2017;42(4):462-468. [Content Brief]
